Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention

International Journal of Clinical Pharmacology Research

Volumn 24, Issue 4, 2004, Pages 129-134

  Yamagishi, S ^a   Nakamura, K ^a   Takeuchi, M ^b   Imaizumi, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DISABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MOLECULAR MECHANICS; MORTALITY; NONHUMAN; OXIDATIVE STRESS; REVIEW; VASCULAR DISEASE;

ANIMALS; ARTERIOSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; POSTPRANDIAL PERIOD;

EID: 14244258183     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339, 229, 1998.
2. Laakso M. Hyperglycemic and cardiovascular disease in type 2 diabetes. Diabetes, 48, 937, 1999.
3. Standl E., Balletshofer B., Dahl B., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project. Diabetologia, 39, 1540, 1996.
4. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 18, 258, 1995.
5. Uusitupa M.I., Niskanen L.K., Siitonen O., Voutilainen E., Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia, 36, 1175, 1993.
6. Kuusisto J., Mykkanen L., Pyorala K., Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes, 43, 960, 1994.
7. Kuusisto J., Mykkanen L., Pyorala K., Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke, 25, 1157, 1994.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPS 33). Lancet, 352, 837, 1998.
9. Qiao Q., Tuomilehto J., Borch-Johnsen K. Post-challenge hyperglycemic is associated with premature death and macrovascular complications. Diabetologia, 46, M17, 2003.
10. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 22, 920, 1999.
11. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet, 354, 617, 1999.
12. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia, 39, 1577, 1996.
13. Ceriello A., Cavarape A., Martinelli L., et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet. Med., 21, 171, 2004.
14. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased intima-media thickness in non-diabetic individuals. Atherosclerosis, 144, 229, 1999.
15. Bonora E., Kiechl S., Oberhollenzer F., et al. Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis: Prospective results from the Bruneck Study. Diabetologia, 43, 156, 2000.
16. Kawamori R., Yamasaki Y., Matsushima H., et al. Prevalence of carotid atherosclerosis in diabetic patients: Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care, 15, 1290, 1992.
17. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature, 404, 787, 2000.
18. Rosen P., Nawroth P. P., King G., et al. The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 17, 189, 2001.
19. Ceriello A. Hyperglycaemia: The bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr. Metab., 12, 42, 1999.
20. Ronson R.S., Nakamura M., Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc. Res., 44, 47, 1999.
21. Creager M.A., Luscher T.F., Cosentino F., Beckman J.A. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 108, 1527, 2003.
22. Kurowska E.M. Nitric oxide therapies in vascular diseases. Curr. Pharm. Des., 8, 155, 2002.
23. Ceriello A., Giacomello R., Stel G., et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes, 44, 924, 1995.
24. Yamagishi S., Edelstein D., Du X.L., Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes, 50, 1491, 2001.
25. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet, 359, 2072, 2002.
26. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA, 290, 486, 2003.
27. Hanefeld M., Chiasson J.L., Koehler C., et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke, 35, 1073, 2004.
28. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur. Heart J., 25, 10, 2004.
29. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int. J. Clin. Pharm. Res., 23, 129, 2003.
30. Nakamura Y., Horii Y., Nishino T., et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol., 43, 1649, 1993.
31. Niwa T., Katsuzaki T., Miyazaki S., et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J. Clin. Invest., 99, 1272, 1997.
32. Schmidt A. M., Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr. Atheroscler. Rep., 2, 430, 2002.
33. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res., 37, 586, 1998.
34. Yamagishi S., Yamamoto Y., Harada S., Hsu C.C., Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett., 384, 103, 1996.
35. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 87, 432, 1991.
36. Yamagishi S., Takeuchi M., Unoki H. Can we identify genes for susceptibility to diabetic microangiopathies using stroke-prone spontaneously hypertensive rat models? Med. Hypo., 56, 510, 2001.
37. Bucala R., Mitchell R., Arnold K., et al. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J. Biol. Chem., 270, 10828, 1995.
38. Lander H.M., Tauras J.M., Ogiste J.S., et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem., 272, 17810, 1997.
39. Vlassara H., Fuh H., Donnelly T., Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol. Med., 1, 447, 1995.
40. Bierhaus A., Illmer T., Kasper M., et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation, 96, 2262, 1997.
41. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 46, 284, 2003.
42. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 275, 25781, 2000.
43. Moulton K.S., Heller E., Konerdling M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation, 99, 1726, 1999.
44. Moulton K.S., Vakili K., Zurakowski D., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. USA, 100, 4736, 2003.
45. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med., 7, 425, 2001.
46. Inoue M., Ueda M., Naruko T., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation, 98, 2108, 1998.
47. Yamagishi S., Yonekura H., Yamamoto Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723, 1997.
48. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 16, 1928, 2002.
49. Yamagishi S., Fujimori H., Yonekura H., Tanaka N., Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem. Biophys. Res. Commun., 258, 353, 1999.
50. Shaw S.S., Schmidt A.M., Banes A.K., et al. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes, 52, 2381, 2003.
51. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med., 4, 1025, 1998.
52. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 106, 2827, 2002.
53. Panagiotopoulos S., O'Brien R.C., Bucala R., Cooper M.E., Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis, 136, 125, 1998.
54. Cai W., Gao Q.D., Zhu L., et al. Oxidative stress-inducing carbonyl compounds from common foods: Novel mediators of cellular dysfunction. Mol. Med., 8, 337, 2002.
55. Lin R.Y., Choudhury R.P., Cai W., et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis, 68, 213, 2003.